Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21 - Trial NCT05452902
Access comprehensive clinical trial information for NCT05452902 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Maryland, Baltimore and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Maryland, Baltimore
Timeline & Enrollment
Phase 2
Sep 01, 2022
Dec 01, 2025
Primary Outcome
CIPN-20 sensory subscale
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe
 side-effect of platinum-based chemotherapy, often used to treat gastrointestinal cancers.
 Unfortunately there are very limited treatments for CIPN. This is a phase II randomized
 controlled trial to test the preliminary efficacy of exercise vs. nutrition education on
 CIPN, to systematically investigate the potential roles of inflammation and interoception,
 and to obtain data with a more accurate effect size to inform a future study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05452902
Non-Device Trial